Shanghai ZhenGe Biotechnology Co.,Ltd. announced that it has received $100,000,000 in its series C round of funding co-led by new investors Goldman Sachs Asset Management, L.P., Sofina Société Anonyme and Novo Holdings A/S on January 11, 2022. The transaction included participation from returning investors Shenzhen Co-win Venture Capital Investments Limited, IDG Capital Partners Co., Ltd., Lyfe Capital, Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, and Junxin (Shanghai) Equity Investment Fund Management Co., Ltd. As a part of the transaction, Kevin Xu, Managing Director at Goldman Sachs Asset Management, L.P., has joined the company's board of directors. The company has raised $225,000,000 in funding till date.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
208 EUR | +2.46% | +3.28% | -7.72% |
Mar. 28 | MORNING BID EUROPE-Yen traders on tenterhooks | RE |
Mar. 02 | India's Byju's can't access rights issue funds to pay staff | RE |
1st Jan change | Capi. | |
---|---|---|
-7.72% | 7.48B | |
+14.99% | 76.73B | |
-9.68% | 18.5B | |
+41.40% | 15.95B | |
+11.92% | 14.88B | |
+5.69% | 13.45B | |
+14.24% | 12.69B | |
+13.11% | 11.89B | |
+38.24% | 11.51B | |
+8.06% | 11.06B |
- Stock
- Equities
- Stock Sofina SA - Euronext Bruxelles
- News Sofina SA
- Shanghai ZhenGe Biotechnology Co.,Ltd. announced that it has received $100 million in funding from a group of investors